{
  "name" : "zero.sci-hub.se_6115_5a71229ff130ad0077b4e12013c8fec2_chen2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy",
    "authors" : [ "Qian Chen", "Jiawen Chen", "Chao Liang", "Liangzhu Feng", "Ziliang Dong", "Xuejiao Song", "Guosheng Song", "Zhuang Liu" ],
    "emails" : [ "zliu@suda.edu.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Journal of Controlled Release xxx (2016) xxx–xxx\nCOREL-08529; No of Pages 11\nContents lists available at ScienceDirect\nJournal of Controlled Release\nj ourna l homepage: www.e lsev ie r .com/ locate / jconre l\nDrug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy\nQian Chen, Jiawen Chen, Chao Liang, Liangzhu Feng, Ziliang Dong, Xuejiao Song, Guosheng Song, Zhuang Liu ⁎ Institute of Functional Nano & Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science and Technology, Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices, Soochow University, Suzhou, Jiangsu 215123, China\n⁎ Corresponding author. E-mail address: zliu@suda.edu.cn (Z. Liu).\nhttp://dx.doi.org/10.1016/j.jconrel.2016.11.006 0168-3659/© 2016 Published by Elsevier B.V.\nPlease cite this article as: Q. Chen, et al., Dr penetration, hypoxia relieve, and s..., J. Contr\na b s t r a c t a r t i c l e i n f o\nArticle history: Received 29 July 2016 Received in revised form 25 October 2016 Accepted 9 November 2016 Available online xxxx\nThe abnormal tumor microenvironment (TME) featured with hypoxia, acidosis, dense extracellular matrix and increased tumor interstitial fluid pressure is closely related with the resistance of tumors to various therapies. Herein, a unique type of biocompatible nanoscale delivery system is fabricated by utilizing a chemotherapeutic drug, paclitaxel (PTX), to induce co-assembly of catalase and human serum albumin (HSA), the latter of which is pre-modified with chlorine e6 (Ce6), forming smart multifunctional HSA-Ce6-Cat–PTX nanoparticles via a rather simple one-step method. Upon intravenous injection, HSA-Ce6-Cat–PTX nanoparticles show high tumor accumulation and efficient intra-tumoral diffusion, likely owning to their changeable sizes that can maintain large initial sizes (~100 nm) during blood circulation and transform into small protein-drug complexes (b20 nm) within the tumor. Meanwhile, catalase within those nanoparticles could trigger decomposition of endogenic TME H2O2 to generate oxygen in-situ so as to relieve tumor hypoxia. This effect together with PTXinduced intra-tumoral perfusion enhancement is able to dramatically modulate TME to favor the anti-tumor effect in the combined photodynamic/chemotherapy with HSA-Ce6-Cat–PTX. Thus, our work presents a simple drug-induced self-assembly strategy to fabricate enzyme-loaded therapeutic albumin nanoparticles for synergistic cancer combination therapy.\n© 2016 Published by Elsevier B.V.\nKeywords: Albumin Self-assembly Deep penetration Hypoxia relieve Combination therapy"
    }, {
      "heading" : "1. Introduction",
      "text" : "Solid tumors, which may be deemed as abnormal organs with heterogeneous structures and unique tumor microenvironment (TME), are composed by many different types of cells (e.g. tumor cells, fibroblasts, inflammatory cells, macrophages, and various types of immune cells) embed in the extracellular matrix and nourished by a vascular network with non-uniform structures [1–4]. The complex composition and structure of tumors contribute to compressed tumor blood vessels and increased tumor interstitial fluid pressure (IFP), whichmay severely hind the penetration of therapeutic agents, particularly nanoparticles with relatively large sizes, during cancer therapy [5–8]. Thus, for the next generation of nanomedicine, the development of size-changeable nanoparticles that could maintain relatively large sizes (50–100 nm) during the blood circulation for effective tumor accumulation via the enhanced permeability and retention (EPR) effect, and dissociate into small particles (below 20 nm) within the tumor for deeper penetration [9–13], would be of great interests. On the other hand, it has been proposed that modulation of TME such as reducing the neoplastic cell\nug-induced co-assembly of a ol. Release (2016), http://dx.d\ndensity to normalize the tumor blood vessels and lower the IFP in the TME, might be another alternative strategy to improve the penetration and distribution of therapeutic nanoparticles within solid tumors [14].\nAnother well-known feature of TME is insufficient oxygen supply, also known as hypoxia, within many types of solid tumors, particularly in the regions far from tumor blood vessels [15,16]. Hypoxia in the tumor is found to be related with the tumor angiogenesis and cancer metastasis, as well as limited therapeutic efficiency of several types of cancer therapies, especially for those with oxygen as a critical component during the cell killing process such as radiotherapy and photodynamic therapy (PDT) [17–22]. To date, various strategies including use of perfluorocarbon-based oxygen-carriers to transport oxygen into tumors [23,24] or in situ generation of oxygen from TME endogenous H2O2 (~50–100 μM), which is produced by the aberrant metabolism of cancer cells [11,25–29], have been explored to relieve the tumor hypoxia and improve therapeutic efficiency. Therefore, it would be of particular attractive to develop nano-theranostics, which on one hand are size-changeable for effective tumor accumulation and diffusion, on the other hand, can modulate tumor microenvironment (e.g. IFP, hypoxia) to achieve better therapeutic outcomes.\nCatalase, an enzymewith specific catalytic behavior in decomposing H2O2 to produce O2, has been explored in recent years to overcome the\nlbumin/catalase as smart nano-theranostics for deep intra-tumoral oi.org/10.1016/j.jconrel.2016.11.006\ntumor hypoxia by in-situ producing oxygen inside the tumor, although its instability in the presence of protease during blood circulation after systemic administration may be a concern [25,30–34]. Thus, various strategies including encapsulation of this enzyme in inorganic nanoparticles or polymeric multilayer capsules have been developed to protect catalase from protease digestion to enable its tumor-targeted delivery [32,35]. However, the relative enzymatic activity of catalase loaded inside nanoparticles is often decreased after those complex synthetic processes [36–38]. In thiswork, inspirited by our previous systems inwhich hydrophobic molecules such as chemotherapeutics or imaging agents are able to induce self-assembly of human serum albumin (HSA) [39– 47], a major component of serum proteins, to form nanoparticles for cancer theranostics, we design a simple and effective method utilizing hydrophobic drug to induce the co-assembly of albumin and catalase to fabricate multifunctional nanoparticles.\nIn our design, HSA pre-modified with chlorine e6 (Ce6), a clinically used photosensitizer, together with catalase, are mixed with an effective antitumor drug, paclitaxel (PTX), the latter of which would trigger co-assembly of proteins to formHSA-Ce6-Cat–PTX nanoparticles. Interestingly, the obtained HSA-Ce6-Cat–PTX nanoparticles show high EPR effect-driven tumor passive homing, together with efficient intratumoral permeability, likely owing to the unique concentration dependent dissociation behavior of those protein-drug nanoparticles. On the other hand, catalase encapsulated within those nanoparticles with largely retained enzyme activity and greatly enhanced stability against protease is able to trigger decomposition of endogenous H2O2 inside the tumor to produceO2 andpromote tumor oxygenation. Furthermore, PTXused in our system, not only is proven to be an effective chemotherapeutic drug, but also has the ability to decompress blood vessels and decrease intra-tumoral IFP, benefiting for intra-tumoral delivery of therapeutic agents and further relieve of tumor hypoxia. With those effects acting simultaneously and synergistically, impressive in vivo therapeutic effect is achieved using such HSA-Ce6-Cat–PTX nanoparticles for tumor treatment under a rather low single treatment dose. Therefore, this work presents a simple one-step approach to fabricate all-proteinbased multifunctional nanoparticles, which not only show changeable sizes for enhanced intra-tumoral accumulation and diffusion, but also are able to modulate the TME such as hypoxia and IFP, so as to realize highly effective combination therapy of cancer."
    }, {
      "heading" : "2. Materials and method",
      "text" : ""
    }, {
      "heading" : "2.1. Materials",
      "text" : "Human serum albumin (HSA), dimethyl sulfoxide (DMSO), N-(3Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride crystalline (EDC), N-Hydroxysuccinimide (NHS) and 3-(4.5-dimethylthiazol-2yl)-2.5-diphenyltetrazolium bromide (MTT) was purchased from Sigma-Aldrich. Chlorine e6 (Ce6) was purchased from J&K Scientific Ltd. Catalase (CAT) solution (≥35,000 units/mg protein) was obtained from Aladdin. Paclitaxel (PTX) was purchased from Beijing ZhongShuo Pharmaceutical Technology Development Co., Ltd. All other chemicals were purchased from China National Pharmaceutical Group Corporation. RPMI-1640 medium was purchased from Thermo Fisher Scientific Inc."
    }, {
      "heading" : "2.2. Synthesis of HSA-Ce6",
      "text" : "Ce6 used during this experimentwas pre-dispersed in DMSO. To obtain HSA-Ce6, 0.01 ml Ce6 (20 mg/ml, 1 eq), 0.064 mg EDC (1 eq) and 0.042 mg NHS (1.1 eq) were mixed in dark for 0.5 h under room temperature. Then the activated Ce6-NHS was added into 2 mg (0.1 eq) HSA dissolved in phosphate buffered saline (PBS). The mixture was stirred overnight in the dark. HSA-Ce6was obtained after centrifugation at 14,800 rpm for 5 min to remove possible aggregates and\nPlease cite this article as: Q. Chen, et al., Drug-induced co-assembly of a penetration, hypoxia relieve, and s..., J. Control. Release (2016), http://dx.d\nultrafiltration by a centrifugal filter device (molecular weight cut-off MWCO= 10 kDa) for 3 times to remove free Ce6."
    }, {
      "heading" : "2.3. Synthesis of different protein nanoparticles",
      "text" : "HSA-Ce6-CAT-PTX nanoparticles were prepared by PTX-induced self-assembly of proteins. 10 mg HSA-Ce6 and 0.1 ml catalase (10 mg/ml measured by BCA) were mixed in 1 ml PBS, into which 65 μl PTX pre-dissolved inmethanol (20mg/ml)was added. The obtained HSA-Ce6-CAT-PTX nanoparticles were purified by centrifugation at 14,800 rpm for 5 min to remove insoluble PTX and then by ultrafiltration using a centrifugal filter device (MWCO = 100 kDa) for 3 times to remove methanol.\nAs the control, HSA-Ce6-PTX without catalase were prepared by the same procedure except that 1 mg plain HSA was used to replace catalase. Furthermore, HSA-Ce6-CAT nanoparticles for control experiments were obtained by cross-linking HSA-Ce6 and CAT (w/w = 10:1) with glutaraldehyde [48]. 10 mg HSA-Ce6 and 1 mg catalase were first dispersed in 1 ml water, and then added with 1 ml ethanol at the rate of 1 ml/min. Afterwards, 10 μl glutaraldehyde (2.5%) was added to the above-mentionedmixture, whichwas then stirred at room temperature overnight. HSA-Ce6-CAT nanoparticles were obtained after dialyzing in a dialysis bag (MWCO 3500 Da) to remove ethanol and glutaraldehyde."
    }, {
      "heading" : "2.4. Characterization",
      "text" : "Transmission electronmicroscopy (TEM, FEI Tecnai F20, acceleration voltage = 200 kV) was used to characterize the morphology of HSACe6-CAT-PTX nanoparticles. UV–vis-NIR absorbance spectra were recorded by PerkiinElmer Lambda 750 UV–vis-NIR spectrophotometer. Fluorescence spectra of different samples were measured with a FluoroMax 4 luminescence spectrometer (HORIBA JobinYvon). The hydrodynamic diameters of different samples were determined by a Zetasizer Nano-ZS (Malvern Instruments, UK)."
    }, {
      "heading" : "2.5. In vitro release of PTX in Hank's solution",
      "text" : "The release of PTX from HSA-Ce6-CAT-PTX dialyzed against Hank's solution (pH 7.4) was carefully studied. 1 ml of HSA-Ce6-CAT-PTX (10 mg/ml HSA, 0.65 mg/ml PTX) was packaged in a dialysis bag (MWCO=14 kDa) and then immersed in 40ml Hank's solution. At different time points (2 h, 6 h, 12 h, 24 h, 48 h), 2 ml of the Hank's solution was collected and the same volume of fresh Hank's solution was added. Then the collected solution was extracted with 1 ml of dichloromethane, evaporated and then followed by adding 1ml of themixture of acetonitrile and water (50:50, v/v). The PTX concentration was measured by high performance liquid chromatography (HPLC)."
    }, {
      "heading" : "2.6. Catalase activity assay",
      "text" : "Catalase activity was determined by the Góth method [49]. Briefly, 1 ml of hydrogen peroxide (50 mM) was added with 0.2 ml of free catalase or HSA-Ce6-CAT-PTX (0.5 μM) for 1 min at 37 °C, and then terminated by adding 1 ml of ammoniummolybdate (32.4 mM) and cooling down to 25 °C. The catalase activity can be determined by the absorbance of the above complex at 400 nm. To measure the stability of catalase, both free catalase and HSA-Ce6-CAT-PTX were incubated with protease K at 37 °C with the final concentration of protease K at 0.4 mg/ml. At predetermined time points, aliquots of sample were removed for immediate catalase activity assay."
    }, {
      "heading" : "2.7. Detection of singlet oxygen",
      "text" : "The method for the singlet oxygen detection was based on the protocol reported previously [50]. In brief, singlet oxygen sensor green reagent (SOSG, molecular probes, USA) dissolved in methanol was\nlbumin/catalase as smart nano-theranostics for deep intra-tumoral oi.org/10.1016/j.jconrel.2016.11.006\nadded to different sample solutions ([SOSG]= 2.5 μM, [Ce6]= 1 μM) to measure SO generation by different samples irradiated by 660-nm light at the power density of 5 mW/cm2 in nitrogen atmosphere. The generated SO was determined by measuring recovered SOSG fluorescence signals at 530 nm under 494-nm excitation."
    }, {
      "heading" : "2.8. Cellular experiments",
      "text" : "Murine breast cancer 4T1 cells were obtained from American Type Culture Collection (ATCC) and cultured in RPMI-1640medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 °C under 5% CO2. To study the cell killing efficacy of those different PTX formulations, 4T1 cells were seeded into 96-well cell culture plates until adherent and then incubated with various concentrations of free PTX, HSA-Ce6-PTX and HSA-Ce6-CAT-PTX for 72 h. The standard thiazolyltetrazolium (MTT, Sigma Aldrich) assay was carried out to determine the cell viabilities relative to control untreated cells.\nFor combination therapy, 4T1 cellswere incubatedwith various concentrations of HSA-Ce6-CAT-PTX, HSA-Ce6-PTX and HSA-Ce6-CAT-PTX. After 4 h of incubation, those samples were irradiated by 660 nm at 5 mW/cm2 for 30 min. After additional incubation for 24 h, the MTT assay was carried out to determine the cell viabilities relative to control untreated cells. Then, themechanism of the combined photodynamic & chemotherapy was studied. 4T1 cells were incubated with HSA-Ce6CAT-PTX (CCe6 = 10 μM) for 4 h and irradiated by the 660-nm light for 30 min. After that, cells were incubated at 37 °C for another 2 h. Before confocal imaging, cells were labeled by Lysotracker (green) and DAPI to staining endosomes/lyosomes and nuclei, respectively.\nFor photodynamic therapy, 4T1 cells seeded in 96-well plates were cultured under nitrogen atmosphere using a hypoxic cell incubator (5% CO2, 94% N2, 1% O2) for 24 h, and then mixed with various concentrations of HSA-Ce6-PTX andHSA-Ce6-CAT-PTX. After 4 h, 100 μMH2O2 were added and then the 96-well plates were exposed to 660 nm light at a power density of 5mW/cm2 for 30min. Then, cellswere transferred into freshmedia and further incubated in normal condition for 24 h. The standard MTT test was then conducted to measure the relative cell viabilities."
    }, {
      "heading" : "2.9. Animal model",
      "text" : "Female nudemicewere purchased fromNanjing Peng Sheng Biological Technology Co Ltd. and used under protocols approved by Soochow University Laboratory Animal Center. To develop the tumor model, 1 × 106 4T1 cells suspended in 50 μL phosphate buffered saline (PBS) were subcutaneously injected into the back of each mouse. The mice were used when tumor volumes reached about 50–60 mm3."
    }, {
      "heading" : "2.10. In vivo imaging",
      "text" : "For in vivo imaging, 200 μL HSA-Ce6, HSA-Ce6-CAT NPs and HSACe6-CAT-PTXwith a 0.5mg/ml Ce6 equivalent concentrationwas intravenously (i.v.) injected into each mouse (Ce6 dose: 5 mg/kg). In vivo fluorescence imagingwas conducted using aMaestro in vivo optical imaging system (Cambridge Research & instrumentation, Inc). The mice were sacrificed 24 h after i.v. injection, with their major organs including the tumor, liver, heart, lung, spleen, and kidneys collected for ex vivo imaging."
    }, {
      "heading" : "2.11. Immunofluorescence",
      "text" : "To study the diffusion of nanoparticles in tumor microenvironment, mice were i.v. injected with HSA-Ce6, HSA-Ce6-CAT NPs or HSA-Ce6CAT-PTX with a 0.5 mg/ml Ce6 equivalent concentration. At 24 h post injection, tumors were surgically excised from themice for immunofluorescence staining. Blood vessel staining was done by incubation with rat anti-CD31 mouse monoclonal antibody (dilution 1:200, Biolegend)\nPlease cite this article as: Q. Chen, et al., Drug-induced co-assembly of a penetration, hypoxia relieve, and s..., J. Control. Release (2016), http://dx.d\nand Rhodamine-conjugated donkey anti-rat secondary antibody (dilution 1:200, Jackson). For tumor hypoxia study, mice were i.v. injected with HSA-Ce6-PTX, HSA-Ce6-CAT NPs or HSA-Ce6-CAT-PTX. 90 min before tumors were surgically excised from the mice (24 h post injection of nanoparticles), pimonidazole hydrochloride (60 mg/kg) (Hypoxyprobe-1 plus kit, Hypoxyprobe Inc),whichwould be reductively activated in hypoxic cells and form stable adductswith thiol (sulphydryl) groups in biomolecules, was intraperitoneally injected into the mice. Then, tumor sections were incubated with mouse anti-pimonidazole antibody (dilution 1:200, Hypoxyprobe Inc.) or anti- HIF-1α antibody (dilution 1:200) overnight, and then Alex 488-conjugated goat antimouse secondary antibody (dilution 1:200, Jackson Inc.) as the secondary antibody following the kit's instructions. Blood vessels were stained by anti-CD31 mouse monoclonal antibody with the same method. The slices were observed by a confocal fluorescence microscopy."
    }, {
      "heading" : "2.12. In vivo combination therapy",
      "text" : "Nude mice bearing subcutaneous 4T1 tumors (~60 mm3) were divided into five groups (n= 5 per group): (a) Untreated; (b) i.v. injected with 200 μl HSA-Ce6-CAT NPs and irradiated by the 660-nm light (5 mW/cm2 for 1 h, irradiated at 24 h p.i.); (c) i.v. injected with 200 μl HSA-Ce6-PTX and under the same light irradiation; (d) i.v. injected with 200 μl HSA-Ce6-CAT-PTXwithout light irradiation; (e) i.v. injected with 200 μl HSA-Ce6-CAT-PTX and under the same light irradiation. The doses of Ce6 and PTXwere kept at 5 mg/kg and 11.6 mg/kg, respectively, in those groups. The tumor sizes were recorded every 2 days for 2 weeks, with their lengths and widths measured by a digital caliper. The tumor volume was calculated according to the following formula: width2 × length / 2."
    }, {
      "heading" : "3. Results and discussion",
      "text" : "Enzyme loaded nanoparticles were synthesized via the hydrophobic drug-induced co-assembly method. As shown in Fig. 1a, HSA was firstly pre-conjugated with a commonly used photodynamic agent (Ce6) via amide bond. Catalase, an enzyme that can rapidly decompose H2O2 to produce O2, was mixed with HSA-Ce6. Then, a clinically used chemotherapeutic drug, PTX, was added to induce the co-assembly of catalase andHSA-Ce6 by hydrophobic interactions. As the control, HSA-Ce6–PTX nanoparticles without catalase were synthesizes by the same method. Besides, HSA-Ce6-Cat NPs obtained by chemical cross-linking of HSACe6 and catalase with glutaraldehyde were prepared as another control (Supporting fig. S1).\nThe obtained HSA-Ce6-Cat–PTX nanoparticles showed uniform spherical structure with average diameter at ~100 nm as revealed by transmission electron microscopy (TEM) imaging (Fig. 1b). Compared to HSA or HSA-Ce6 complex that showed hydrodynamic size at 7– 8 nm, HSA-Ce6–PTX and HSA-Ce6-Cat–PTX showedmuch larger hydrodynamic diameters to be ~100 nm, indicating the successful assembly of albumins and catalase into nanoparticles induced by PTX (Fig. 1c). The UV–Vis-NIR absorption spectra of different nanoparticles were also measured (Fig. 1d). Notably, the absorption peak of Ce6 shifted from ~642 nm for free Ce6 to ~660 nm in HSA-Ce6, likely a result from the chemical bonding between Ce6 and HSA. The Ce6 and PTX contents in these different nanoparticles were tuned to be similar at 2.6% and 6.5%, which were determined by UV–vis absorbance spectra and high performance liquid chromatography (HPLC), respectively. Moreover, loaded PTX in the nanoparticleswould be slowly released to enable cancer cell killing for chemotherapy (Supporting fig. S2).\nCatalase, which has the ability to rapidly decompose H2O2 into H2O and O2, has been reported by many groups as an O2-envolving agent [34,51]. Therefore, the generation of O2 in the solution of HSA-Ce6-Cat NPs and HSA-Ce6-Cat–PTX containing 100 μM H2O2 was measured by an oxygen probe (JPBJ-608 portable Dissolved OxygenMeters, Shanghai REX Instrument Factory). Compared to free catalase, both HSA-Ce6-Cat\nlbumin/catalase as smart nano-theranostics for deep intra-tumoral oi.org/10.1016/j.jconrel.2016.11.006\nFig. 1. Synthesis and characterization of HSA-Ce6-CAT-PTX nanoparticles. (a) Scheme illustration for the synthesis of HSA-Ce6-CAT-PTX nanoparticles. (b) A TEM image of HSA-Ce6-CATPTX nanoparticles. (c) Hydrodynamic diameters of HSA, HSA-Ce6, HSA-Ce6-PTX, HSA-Ce6-CATNPs and HSA-Ce6-CAT-PTXmeasured by DLS. (d) UV–vis-NIR spectra of free HSA, free Ce6, HSA-Ce6, HSA-Ce6-PTX, HSA-Ce6-CAT NPs and HSA-Ce6-CAT-PTX nanoparticles. (e) Oxygen generation in H2O2 solutions added with free CAT, HSA-Ce6-CAT NPs or HSA-Ce6-CAT-PTX (the same protein concentration). (f) The generation of singlet oxygen determined by the increased SOSG fluorescence, for HSA-Ce6-PTX or HSA- Ce6-CAT-PTXwith orwithout addition of H2O2. (g) The relative enzymatic activity changes of free catalase and HSA-CAT-PTX after protease K digestion for different periods of time.\nNPs andHSA-Ce6-Cat–PTX have the ability to trigger the decomposition of H2O2 to produce O2 quickly. Excitingly, HSA-Ce6-Cat-PTX nanoparticles producedmore oxygen than HSA-Ce6-Cat NPs owning to that catalase loaded in HSA-Ce6-Cat NPs might lose some of its activity during the synthetic process in which chemical crosslinking was involved. However, in the absence of catalase-containing nanoparticles, H2O2 solutionwas rather stable and generated negligible O2 (Fig. 1e). Encouraged by the effective O2 production from H2O2 in the presence of HSA-Ce6-Cat–PTX, we wondered whether the produced O2 would be beneficial for singlet oxygen (SO) generation during the photodynamic therapy. The generation of SO produced byHSA-Ce6–PTX andHSA-Ce6Cat–PTX with the same Ce6 concentration in the presence of 100 μM H2O2, which was used to mimic the tumor microenvironment, was measured by the singlet oxygen sensor green (SOSG) probe. As expected, in the absence of H2O2, HSA-Ce6–PTX and HSA-Ce6-Cat–PTX showed similar SO generation efficiency. Interestingly, in the presence of H2O2, the generation of SO by HSA-Ce6-Cat–PTX was remarkably higher owing to the additional O2 supply generated by H2O2 in the presence of catalase (Fig. 1f). Therefore, the PDT efficiency of HSACe6-Cat–PTX is expected to be significantly improved in the tumor microenvironment containing a certain amount of H2O2 [34,52].\nCatalase is known to be a specific enzyme in decomposing H2O2 to produce O2, but may lose their activities in vivo owning to the complex\nPlease cite this article as: Q. Chen, et al., Drug-induced co-assembly of a penetration, hypoxia relieve, and s..., J. Control. Release (2016), http://dx.d\nphysiological environment in the presence of proteases. We thus wondered whether entrapment of catalase in the albumin nanoparticles may be helpful to increase the stability of enzymes by protecting them from the protease digestion. The catalase activity of HSA-Ce6-Cat–PTX against proteases was determined by the Góth method [49]. Compared to free catalase, most of which was digested and lost its activity rapidly upon exposure to protease K (0.1 mg/ml), catalase entrapped in albumins in theHSA-Ce6-Cat–PTX formulationmaintained ~70% of its initial enzymatic activity after incubation with protease K for 24 h (Fig. 1g). Therefore, catalase after encapsulation in albumin nanoparticles has been well protected, important for its in vivo tumor-targeted delivery via systemic administration.\nIn vitro experiments were then carried out to investigate the therapeutic efficiency of different nanoparticles. Firstly, all the three PTX formulations including free PTX (dissolved in 1:1 (v/v) mixture of Cremophor EL and ethanol), HSA-Ce6-PTX and HSA-Ce6-Cat–PTX showed similar cytotoxicity towards 4T1 murine breast cancer cells (Fig. 2a). To study the cellular uptake efficiency of different nanoparticles, cells were incubated with free Ce6, HSA-Ce6, HSA-Ce6-Cat NPs, and HSA-Ce6-Cat–PTX, respectively, at the same Ce6 concentration for different periods of time. Confocalfluorescence imaging results revealed remarkably higher Ce6 fluorescence in cells incubated with HSA-Ce6Cat NPs and HSA-Ce6-Cat–PTX compared to those incubated with free\nlbumin/catalase as smart nano-theranostics for deep intra-tumoral oi.org/10.1016/j.jconrel.2016.11.006\nFig. 2. In vitro cell culture experiments. (c) Relative viabilities of 4T1 cells after incubation with various concentrations of free PTX, HAS-Ce6-PTX, HSA-Ce6-CAT-PTX for 72 h. (d) Relative viabilities of 4 T1 cells after incubationwithHSA-Ce6-CAT-PTX orHSA-Ce6-CATNPswith orwithout 660-nm light irradiation (5mW/cm2, 30min). (c) Confocalfluorescence images of 4T1 cells incubated with HSA-Ce6-CAT-PTX before and after 660-nm light irradiation. Green, red, and blue colors represented Lyso-Tracker stained endosomes/lysosomes, Ce6 fluorescence, and DAPI-stained cell nuclei, respectively. (d) Relative viabilities of 4T1 cells cultured under the nitrogen atmosphere after incubation with HSA-Ce6-PTX or HSA-Ce6-CAT-PTX with or without addition of H2O2 under 660-nm light irradiation (L+). (For interpretation of the references to colour in this figure legend, the reader is referred to theweb version of this article.)\nCe6, indicated that the cellular uptake efficiency of Ce6would be greatly improved after being incorporated into protein-nanoparticles (Supporting fig. S3).\nNext, the in vitro combination therapy with our HSA-Ce6-Cat–PTX was evaluated. 4T1 murine breast cancer cells were incubated with HSA-Ce6-Cat NPs or HSA-Ce6-Cat–PTX at various concentrations for 4 h, and the exposed with 660 nm LED light irradiation at the power density of 5 mW/cm2 for 30 min. Cells treated with HSA-Ce6-Cat–PTX in dark without light exposure was used as a control. After incubation for another 24 h, the standard cell viability assay was carried out to measure the relative cell viabilities in different groups. Compared to chemotherapy alone with HSA-Ce6-Cat–PTX (in dark), or PDT alone with HSA-Ce6-Cat NPs under light irradiation, the combination treatment by HSA-Ce6-Cat–PTX under light irradiation showed obvious synergistic effect in killing cancer cells (Fig. 2b).To investigate themechanism of synergistic effect by combined photodynamic & chemotherapy, cells were imaged by a confocal fluorescence microscope before and after the 660-nm light irradiation for 30 min (Fig. 2c). Before laser irradiation, the fluorescence of Ce6 showed good co-localization with endo/lysosomes, which were stained by Lysotracker. Interestingly, after laser irradiation, the diffused Ce6 fluorescence as well as the reduced Lysotracker fluorescence were observed, indicating that the photochemical internalization [53] trigger the release of the chemotherapeutic drugs into cytoplasm, resulting in the improved therapeutic efficiency.\nConsidering catalase has the ability to decompose endogenous H2O2 within the tumor to produce oxygen [25,54,55], we then examined the therapeutic efficiency of HSA-Ce6–PTX and HSA-Ce6-Cat–PTX to 4T1 cells cultured under nitrogen atmosphere (5% CO2, 94% N2, 1% O2) for 24 h. After the incubation, exogenous 100 μM H2O2 was added to mimic the tumor microenvironment for laser irradiation. Afterwards, cells were incubated under standard atmosphere for another 24 h before the cell viability assay. Owing to the insufficient oxygen supply under the nitrogen atmosphere, the therapeutic efficiency of HSA-Ce6PTX with light exposure to trigger PDT appeared to be much lower at the tested doses even with exogenous H2O2 added. In contrast, the cancer cell killing efficiency of HSA-Ce6-Cat–PTX with light exposure\nPlease cite this article as: Q. Chen, et al., Drug-induced co-assembly of a penetration, hypoxia relieve, and s..., J. Control. Release (2016), http://dx.d\ncould be dramatically enhanced with exogenous H2O2 (100 μM) added (Fig. 2d), owing to the additional oxygen generated from catalase-triggered decomposition of H2O2 to promote PDT within the nitrogen atmosphere. Therefore, HSA-Ce6-Cat–PTX appears to be an efficient combination therapy agent even within the hypoxic tumor microenvironment.\nEncouraged by the excellent biocompatibility of our albumin-based HSA-Ce6-CAT-PTX nanoparticles, which showed negligible hemolysis at all tested concentrations (Supporting fig. S4), we then carried out the in vivo experiment. To study the pharmacokinetics of different nanoparticles, mice were intravenously (i.v.) injected with HSA-Ce6, HSA-Ce6-Cat NPs, or HSA-Ce6-Cat–PTX at the same dose of Ce6 (5mg/kg). Based on Ce6 fluorescence in the blood samples taken at different time points post injection (p.i.), the blood circulation half-lives of HSA-Ce6-Cat NPs and HSA-Ce6-Cat–PTX (HSA-Ce6-Cat NPs t1/2 (α) = 5.66 ± 1.26 h, t1/2(β) = 11.28 ± 2.22 h; HSA-Ce6-Cat–PTX t1/2 (α) = 2.67±0.68 h, t1/2(β)=7.11±0.54 h)weremeasured to be significantly prolonged compared to that of HSA-Ce6 (t1/2(α)= 0.43±0.28 h, t1/2(β)= 5.39 ± 0.36 h), owing to the enlarged nanoparticle sizes to prevent the rapid clearance of individual albumin complexes (Supporting fig. S5). Next, mice bearing subcutaneous 4T1 tumors after i.v. injection of different nanoparticles were imaged by a Maestro EX in vivo imaging system at different time points. The fluorescence of Ce6 distributed all over the mouse body after injection of the three nanoparticles at early time points. Later on, both HSA-Ce6-Cat NPs and HSA-Ce6-Cat–PTX showed obvious tumor accumulation, while the fluorescence signals from mice injected with HSA-Ce6 decreased over time with less obvious tumor contrast, owning to the rapid clearance of HSA-Ce6 (Fig. 3a & b). The semi-quantitative biodistribution of these nanoparticles based on ex vivo imaging of tumors and major organs collected from mice at 24 h p.i. further confirmed the higher tumor uptake of HSA-Ce6-Cat NPs and HSA-Ce6-Cat–PTX due to their prolonged blood circulation (Fig. 3a & c).\nBased on our previous studies [39,40], the stability of albumin nanoparticles induced by hydrophobic drug molecules (e.g. paclitaxel) is concentration dependent. Then, we carefully compared the stability of albumin nanoparticles obtained by drug-induced self-assembly or\nlbumin/catalase as smart nano-theranostics for deep intra-tumoral oi.org/10.1016/j.jconrel.2016.11.006\nFig. 3. The accumulation and diffusion of protein nanoparticles in the tumor. (a) In vivo fluorescence images of 4T1 tumor-bearing nude mice taken at different time points post i.v. injection of HSA-Ce6, HSA-Ce6-Cat NPs, or HSA-Ce6-Cat-PTX. The right column shows ex vivo fluorescence images of major organs and tumor dissected from those mice at 24 h p.i. Tu, Li, Sp, Ki, H, and Lu stand for tumor, liver, spleen, kidney, heart, and lung, respectively. (b) Relative fluorescence intensities of tumors from different groups of mice at various time intervals based on in vivo fluorescence images shown in (a). (c) Quantification of ex vivo fluorescence images for different organs (24 h p.i.) in (a). (d) Confocal fluorescence images of tumor slices collected from mice 24 post injection of HSA-Ce6, HSA-Ce6-Cat NPs, or HSA-Ce6-Cat-PTX. The green and red signals were from the fluorescence of Ce6 and anti-CD31stained blood vessels, respectively. (d) The statistics of Pearson's correlation coefficient (Rr) from (c). A higher value of Rr indicates a higher level of co-localization between two types of fluorescent signals (nanoparticles and blood vessels). (f) The scheme shows the dissociation behavior of HSA-Ce6-Cat-PTX after dilution. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)\nchemical cross-linking. Themeasured hydrodynamic diameters indicated that HSA-Ce6-Cat–PTX would gradually dissociate upon dilution, while HSA-Ce6-Cat NPs obtained by chemical cross-linking were rather stable at different concentrations (Supporting fig. S6). Thus, we\nwondered whether this unique concentration-dependent stability of HSA-Ce6-Cat–PTX may show the advantage for deep penetration in the tumor with quite complex structures. Mice after i.v. injection of HSA-Ce6, HSA-Ce6-Cat NPs and HSA-Ce6-Cat–PTX were scarified for\nesentative 2D PA images of 4T1 solid tumors onmice before and 24 h after i.v. injection of\nsaturation levels in tumors were determined by measuring PA signals of deoxygenated\nof the oxyhemoglobin saturation in the tumor before and 24 post injection of different\nining. The hypoxia areas and blood vessels were stained by antipimonidazole antibody\n(e) positive areas and blood vessel densities as recorded from N10 micrographs for each\nating with different agents. Microbubbles were intravenously injected as the ultrasound\ntime. (For interpretation of the references to colour in this figure legend, the reader is\nPlease cite this article as: Q. Chen, et al., Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and s..., J. Control. Release (2016), http://dx.doi.org/10.1016/j.jconrel.2016.11.006\nimmunofluorescent staining of tumor slices. In tumors from mice after injection with HSA-Ce6-Cat–PTX, a great deal of Ce6 signals (green) was found to locate far from blood vessels stained with anti-CD31 antibody (red). In contrast, in tumors frommice after injection of HSA-Ce6Cat NPs, the fluorescence signals were mostly co-localized with tumor blood vessels. Moreover, for tumors from mice with injection of HSACe6, the Ce6 signals were found to be dispersed but ratherweak owning their low tumor accumulation (Fig. 3d & e). Therefore, although individual albumin complexeswith small sizes (b20 nm) show excellent interstitial diffusion ability inside the tumor, their tumor retention is usually limited if they are directly injected due to their short blood half-lives. On the other hand, chemically cross-linked albumin nanoparticles with large sizes (~100 nm) appear to show excellent passive tumor accumulation by the EPR effect owning to their prolonged blood circulation. However, the tumor-associated fibroblasts and dense extracellular matrix will limit their interstitial penetration within the tumor. Remarkably, HSA-Ce6-Cat–PTX with unique concentration-dependent dissociation ability could be ideal nanomedicine particles which show relatively large sizes (50–100 nm) during blood circulation at high concentrations for effective tumor accumulation, and could gradually dissociate into smaller albumin-drug complexes upon dilution after entering the tumor, so as to enable enhanced penetration inside the tumor (Fig. 3f).\nNext, we ought to study the possible changes of TME for tumors on mice after injection of various types of nanoparticles developed in our study. Photoacoustic imaging (PA) has been a standardmethod tomeasure oxygenation levels in different tissues by utilizing the absorbance spectra shift between oxygenated hemoglobin and deoxygenated hemoglobin [56,57]. In order to study catalase loaded nanoparticles on reducing the tumor hypoxia, PA imaging was used to monitor the oxygenation status in tumors based on signals of oxygenated and deoxygenated hemoglobin at 850 and 750 nm, respectively [56–59]. Mice bearing 4 T1 tumors were imaged by a Vevo LAZR Imaging System (FujiFilmVisualSonics Inc.) before and24h post i.v. injection of different nanoparticles. It was found that the blood oxyhemoglobin level in tumors of mice after injection with HSA-Ce6-Cat–PTX showed significant increase, while no obvious changewas observed in tumors of micewith injection of HSA-Ce6-Cat NPs (Fig. 4a & b). Such a difference may likely be attributed to the less efficient intra-tumoral penetration of HSA-Ce6Cat NPs with fixed sizes. Interestingly, for tumors onmice injected with HSA-Ce6-PTX, the oxyhemoglobin level also showed significant enhancement, although not as high as that in theHSA-Ce6-Cat–PTX group.\nTo further versify the change of hypoxia status within tumors of mice after treatment with various types of nanoparticles, hypoxia-inducible factor (HIF)-1α and hypoxia-probe (pimonidazole) immunofluorescence staining assays were carried out on tumor slices from mice 24 h post injection of different nanoparticles. In addition to hypoxia staining with either anti-pimonidazole antibody or anti-HIF-1α antibody, cell nuclei and tumor blood vessels were stained with 2-(4- amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) (blue) and anti-CD31 antibody (red), respectively. Compared to untreated tumors with large hypoxia areas, tumors from mice injected with HSACe6-Cat NPs showed greatly reduced hypoxia signals despite no significant enhance in tumor blood oxyhemoglobin level was noted from PA imaging in this group. Notably, nearly no anti-pimonidazole or antiHIF-1α stained hypoxia signals were found in tumors frommice treated with HSA-Ce6-Cat–PTX, suggesting the dramatically relieved tumor hypoxia in this group. Consistent with PA imaging results, we found that tumor slices from mice injected with HSA-Ce6-PTX also showed significantly decreased hypoxia signals compared to the untreated control (Fig. 4c). Semi-quantitative statistical analysis of hypoxia and HIF-1α positive areas based on N10 confocal images further indicated that tumor hypoxia was successfully relieved by both PTX and catalase (Fig. 4d & e).\nTo under why PTX-loaded nanoparticles could relieve tumor hypoxia and study the changes in tumor structures after different\nPlease cite this article as: Q. Chen, et al., Drug-induced co-assembly of a penetration, hypoxia relieve, and s..., J. Control. Release (2016), http://dx.d\nnanoparticles treatment, the blood perfusion inside tumors of mice after different treatment was studied by ultrasound imaging (FujiFilm VisualSonics Inc.) with a commercial microbubble contrast agent (Fig. 4f & g). Tumors from untreated mice as well as mice with injection of HSA-Ce6-Cat NPs showed enhanced ultrasound signals only in the surrounding areas of tumors. Oppositely, strong ultrasound signals dispersed throughout the whole tumors from mice after treatment with HSA-Ce6–PTX or HSA-Ce6-Cat–PTX (24 h post injection)were observed right after i.v. injection of microbubbles, indicating the obviously improved tumor perfusion after PTX treatment. Therefore, owning to the catalase-induced decomposition of endogenic H2O2 in the TME, the tumor hypoxia status could be relieved after i.v. injection of catalaseloaded nanoparticles (HSA-Ce6-Cat NPs and HSA-Ce6-Cat–PTX). However, the tumor oxygen level enhancement for the HSA-Ce6-Cat NPs treated group was not high enough to affect the blood oxyhemoglobin level as revealed by PA imaging. On the other hand, it is known that Taxanes including PTX is able to induce apoptosis of neoplastic cells so as to decompress tumor blood vessels and lower interstitial fluid pressure in the tumor [46]. Such an effect would result in enhanced intratumoral perfusion and thus lead to relieve of tumor hypoxia (more oxygen delivery into tumors via blood flow.\nMotivated by the efficient accumulation and deep intra-tumoral penetration of HSA-Ce6-Cat–PTX in the tumor together with its ability to relieve the tumor hypoxia, we carried out the combination therapy in vivo with the 4T1 tumor model. Mice bearing 4T1 tumors were randomly divided into five groups (n = 5 per group): untreated, HSACe6-Cat NPs with light irradiation (660 nm, 5 mW/cm2 for 1 h, irradiated at 24 h p.i.), HSA-Ce6–PTX with light, HSA-Ce6-Cat–PTX without light, and HSA-Ce6-Cat–PTX with light (dose: Ce6 5 mg/kg, PTX 11.6mg/kg, Cat 15mg/kg). After various treatments, the tumor volumes weremonitored every two days by a caliper. Excitingly, mice after combination therapy with HSA-Ce6-Cat–PTX showed the most effective tumor growth inhibition effect among various control groups including photodynamic therapy alone with HSA-Ce6-Cat NPs (L+), or chemotherapy alone with HSA-Ce6-Cat–PTX (L-), after which the tumor growthswere only partially delayed (Fig. 5a & b, Supportingfig. S6). Notably, owing to the presence of catalase to further relieve tumor hypoxia, treatment with HSA-Ce6-Cat–PTX (L+) appeared to be obviously more effective compared to treatment with HSA-Ce6–PTX (L+), which was also the combination therapy but without the help of catalase. Hematoxylin and eosin (H&E) staining of tumor slices collected 1 day after various treatment revealed severe damages in cancer cells after the combination treatment using HSA-Ce6-Cat–PTX, while cells in the other control groups were less or nearly not damaged (Fig. 5c).\nAlthough intelligent albumin-MnO2 nanoparticles developed in our previous work are pH-/H2O2-responsive dissociable nano-carriers and have the ability tomodulate tumor hypoxia, the safety issues of inorganic component in the previous formulation and the significant amount of released Mn2+ may be concerns to be addressed before its clinical translation [8]. Notably, all-protein-based HSA-Ce6-Cat–PTX nanoparticles developed here by drug-induced assembly of proteins show great biocompatibility, and could be utilized for effective combination therapy owning to several factors as shown in the scheme (Fig. 6). (1) HSACe6-Cat–PTX nanoparticles with sizes at ~100 nm are suitable for efficient tumor accumulation by the EPR effect owning to their prolonged blood circulation. In future,wemay further incorporate tumor-targeting ligands into those albumin-based nanoparticles also by drug-induced self-assembly to realize active tumor targeting [39]. (2) HSA-Ce6-Cat– PTX nanoparticles may gradually decomposed into therapeutic albumin-drug complexes with small sizes within the tumor owning to their concentration-dependent dissociation behavior, leading to greatly enhanced intra-tumoral permeability. (3) PTX delivered into tumors may decompress tumor blood vessels and decrease tumor microvascular pressure, favorable for intra-tumoral delivery of therapeutic agents as well as oxygen. (4) Catalase after entrapped in albumins keeps high catalytic activity in decomposing TME endogenous H2O2 to produce O2, and\nlbumin/catalase as smart nano-theranostics for deep intra-tumoral oi.org/10.1016/j.jconrel.2016.11.006\nFig. 5. In vivo combination therapy. (a) Tumor growth curves ofmice indifferent groups including untreated control (1), HSA-Ce6-CatNPs injection plus light irradiation (2), HSA-Ce6-PTX injection plus light irradiation (3), HSA-Ce6-Cat-PTX injection without light irradiation (4) or with light irradiation (5) (n = 5 per group). Light irradiation (+L) was conducted by the 660 nm LED light at the power density of 5 mW/cm2 for 1 h. (b) Average weight of tumors collected from mice 14 days after different treatments were initiated. P values in were calculated by Tukey's post-test (*** p b 0.001, ** p b 0.01, or * p b 0.05) by comparing other groups with the last group HSA-Ce6-Cat-PTX (+L) (c) H&E stained tumor slices from different groups collected 24 h after light irradiation.\ncould thus relieve tumor hypoxia to improve photodynamic efficiency. (5) Photodynamic therapy would induce the disruption of endo/ lysosomes, which in turn may trigger the chemotherapeutic drug\nPlease cite this article as: Q. Chen, et al., Drug-induced co-assembly of a penetration, hypoxia relieve, and s..., J. Control. Release (2016), http://dx.d\nredistribution into cytoplasm to improve the therapeutic efficiency. Thosemany factors taken togethermay result in effective cancer combination therapy after the TME is modulated in favor of cancer treatment.\nbination therapy with HSA-Ce6-Cat-PTX nanoparticles.\nlbumin/catalase as smart nano-theranostics for deep intra-tumoral oi.org/10.1016/j.jconrel.2016.11.006"
    }, {
      "heading" : "4. Conclusion",
      "text" : "In conclusion, multifunctional HSA-Ce6-Cat–PTX protein-drug nanoparticles are successfully fabricated via chemotherapeutic drug induced self-assembly of proteins for effective cancer combination therapy via modulating TME through different mechanisms. Such HSA-Ce6Cat–PTX nanoparticles show efficient tumor passive accumulation and effective intra-tumoral diffusion, likely owing to the concentration-dependent dissociation behavior of those self-assembled protein-drug nanoparticles, as well as the ability of PTX to promote tumor perfusion, the latter of which is also helpful to relieve tumor hypoxia. Meanwhile, HSA-Ce6-Cat–PTX accumulated in the tumor could induce the decomposition of tumor endogenous H2O2 to produce O2, further improving tumor oxygenation to enhance the efficacy of photodynamic therapy used in combination with chemotherapy. Such enzyme-loaded multifunctional theranostic nanoparticles are all-protein-based nanoparticles assembled with the help of a chemotherapeutic drugwithout using any covalent chemistry. The components are safe and the fabrication process is rather simple in our system, particularly favorable for future clinical translation."
    }, {
      "heading" : "Acknowledgment",
      "text" : "This work was partially supported by the National Research Programs from Ministry of Science and Technology (MOST) of China (2016YFA0201200), the National Natural Science Foundation of China (51525203), a Juangsu Natural Science Fund for Distinguished Young Scholars (BK20130005), Collaborative Innovation Center of Suzhou Nano Science and Technology, and a Project Funded by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions."
    }, {
      "heading" : "Appendix A. Supplementary data",
      "text" : "Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.jconrel.2016.11.006."
    } ],
    "references" : [ {
      "title" : "Drug resistance and the solid tumor microenvironment",
      "author" : [ "O. Trédan", "C.M. Galmarini", "K. Patel", "I.F. Tannock" ],
      "venue" : "J. Natl. Cancer I. 99 ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Immunological hallmarks of stromal cells in the tumour microenvironment",
      "author" : [ "S.J. Turley", "V. Cremasco", "J.L. Astarita" ],
      "venue" : "Nat. Rev. Immunol. 15 ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Polypyrrole-based nanotheranostics for activatable fluorescence imaging and chemo/photothermal dual therapy of triplenegative breast cancer",
      "author" : [ "D. Park", "K.-O. Ahn", "K.-C. Jeong", "Y. Choi" ],
      "venue" : "Nanotechnology 27 ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Real-time in vivo visualization of tumor therapy by a near-infrared-II Ag2S quantum dot-based theranostic nanoplatform",
      "author" : [ "F. Hu", "C. Li", "Y. Zhang", "M. Wang", "D. Wu", "Q. Wang" ],
      "venue" : "Nano Res. 8 ",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Drug penetration in solid tumours",
      "author" : [ "A.I. Minchinton", "I.F. Tannock" ],
      "venue" : "Nat. Rev. Cancer 6 ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "A nanoparticle size series for in vivo fluorescence imaging",
      "author" : [ "Z. Popović", "W. Liu", "V.P. Chauhan", "J. Lee", "C. Wong", "A.B. Greytak", "N. Insin", "D.G. Nocera", "D. Fukumura", "R.K. Jain" ],
      "venue" : "Angew. Chem. 122 ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Size-dependent tumor penetration and in vivo efficacy of monodisperse drug–silica nanoconjugates",
      "author" : [ "L. Tang", "N.P. Gabrielson", "F.M. Uckun", "T.M. Fan", "J. Cheng" ],
      "venue" : "Mol. Pharm. 10 ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Bioorthogonal turn-on probe based on aggregation-induced emission characteristics for cancer cell imaging and ablation",
      "author" : [ "Y. Yuan", "S. Xu", "X. Cheng", "X. Cai", "B. Liu" ],
      "venue" : "Angew. Chem. Int. Ed. 55 ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy",
      "author" : [ "H.-J. Li", "J.-Z. Du", "X.-J. Du", "C.-F. Xu", "C.-Y. Sun", "H.-X. Wang", "Z.-T. Cao", "X.-Z. Yang", "Y.-H. Zhu", "S. Nie" ],
      "venue" : "Proc. Natl. Acad.Sci. 113 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration",
      "author" : [ "H.-J. Li", "J.-Z. Du", "J. Liu", "X.-J. Du", "S. Shen", "Y.-H. Zhu", "X. Wang", "X. Ye", "S. Nie", "J. Wang" ],
      "venue" : "ACS Nano 10 ",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Intelligent albumin–MnO2 nanoparticles as pH−/H2O2-responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy",
      "author" : [ "Q. Chen", "L. Feng", "J. Liu", "W. Zhu", "Z. Dong", "Y. Wu", "Z. Liu" ],
      "venue" : "Adv. Mater. 28 ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "The role of micelle size in tumor accumulation",
      "author" : [ "J. Wang", "W. Mao", "L.L. Lock", "J. Tang", "M. Sui", "W. Sun", "H. Cui", "D. Xu", "Y. Shen" ],
      "venue" : "penetration, and treatment, ACS Nano 9 (2015) 7195–7206. Please cite this article as: Q. Chen, et al., Drug-induced co-assembly of a penetration, hypoxia relieve, and s..., J. Control. Release ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nanoscale theranostics for physical stimulus-responsive cancer therapies",
      "author" : [ "Q. Chen", "H. Ke", "Z. Dai", "Z. Liu" ],
      "venue" : "Biomaterials 73 ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "High interstitial fluid pressure—an obstacle in cancer therapy",
      "author" : [ "C.-H. Heldin", "K. Rubin", "K. Pietras", "A. Östman" ],
      "venue" : "Nat. Rev. Cancer 4 ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis",
      "author" : [ "R.-C. Ji" ],
      "venue" : "Cancer Lett. 346 ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma",
      "author" : [ "Y.-L. Hu", "M. DeLay", "A. Jahangiri", "A.M. Molinaro", "S.D. Rose", "W.S. Carbonell", "M.K. Aghi" ],
      "venue" : "Cancer Res. 72 ",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Targeting HIF-1 for cancer therapy",
      "author" : [ "G.L. Semenza" ],
      "venue" : "Nat. Rev. Cancer 3 ",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer",
      "author" : [ "M. Milosevic", "P. Warde", "C. Ménard", "P. Chung", "A. Toi", "A. Ishkanian", "M. McLean", "M. Pintilie", "J. Sykes", "M. Gospodarowicz" ],
      "venue" : "Clin. Cancer Res. 18 ",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Targeting hypoxia",
      "author" : [ "T.W. Meijer", "J.H. Kaanders", "P.N. Span", "J. Bussink" ],
      "venue" : "HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy, Clin. Cancer Res. 18 ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Imaging hypoxia to improve radiotherapy outcome",
      "author" : [ "M.R. Horsman", "L.S. Mortensen", "J.B. Petersen", "M. Busk", "J. Overgaard" ],
      "venue" : "Nat. Rev. Clin. Oncol. 9 ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "A",
      "author" : [ "Y. Lou", "P.C. McDonald", "A. Oloumi", "S. Chia", "C. Ostlund", "A. Ahmadi" ],
      "venue" : "Kyle, U.a.d. Keller, S. Leung, D. Huntsman, Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors, Cancer Res. 71 ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Mesoporous silica nanorods intrinsically doped with photosensitizers as a multifunctional drug carrier for combination therapy of cancer",
      "author" : [ "G. Yang", "H. Gong", "X. Qian", "P. Tan", "Z. Li", "T. Liu", "J. Liu", "Y. Li", "Z. Liu" ],
      "venue" : "Nano Res. 8 ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "X",
      "author" : [ "Y. Cheng", "H. Cheng", "C. Jiang" ],
      "venue" : "Qiu, K.Wang, W. Huan, A. Yuan, J. Wu, Y. Hu, Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy, Nat. Commun. 6 ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Perfluorocarbon-loaded hollow Bi2Se3 nanoparticles for timely supply of oxygen under near-infrared light to enhance the radiotherapy of cancer",
      "author" : [ "G. Song", "C. Liang", "X. Yi", "Q. Zhao", "L. Cheng", "K. Yang", "Z. Liu" ],
      "venue" : "Adv. Mater. 28 ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Catalase-loaded TaOx Nanoshells as bio-Nanoreactors combining high-Z element and enzyme delivery for enhancing radiotherapy",
      "author" : [ "G. Song", "Y. Chen", "C. Liang", "X. Yi", "J. Liu", "X. Sun", "S. Shen", "K. Yang", "Z. Liu" ],
      "venue" : "Adv. Mater. 28 ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Modulation of hypoxia in solid tumor microenvironment with MnO2 nanoparticles to enhance photodynamic therapy",
      "author" : [ "W. Zhu", "Z. Dong", "T. Fu", "J. Liu", "Q. Chen", "Y. Li", "R. Zhu", "L. Xu", "Z. Liu" ],
      "venue" : "Adv. Funct. Mater. 26 ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Intelligent MnO2 Nanosheets anchored with Upconversion Nanoprobes for concurrent pH−/H2O2responsive UCL imaging and oxygen-elevated synergetic therapy",
      "author" : [ "W. Fan", "W. Bu", "B. Shen", "Q. He", "Z. Cui", "Y. Liu", "X. Zheng", "K. Zhao", "J. Shi" ],
      "venue" : "Adv. Mater. 27 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Probing hydroxyl radical generation from H2O2 upon plasmon excitation of gold nanorods using electron spin resonance: molecular oxygen-mediated activation",
      "author" : [ "T. Wen", "H. Zhang", "Y. Chong", "W.G. Wamer", "J.-J. Yin", "X. Wu" ],
      "venue" : "Nano Res. 9 ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "An implantable depot that can generate oxygen in situ for overcoming hypoxia-induced resistance to anticancer drugs in chemotherapy",
      "author" : [ "C.-C. Huang", "W.-T. Chia", "M.-F. Chung", "K.-J. Lin", "C.-W. Hsiao", "C. Jin", "W.-H. Lim", "C.-C. Chen", "H.-W. Sung" ],
      "venue" : "J. Am. Chem. Soc. 138 ",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "The catalase-peroxidase gene and isoniazid resistance of mycobacterium tuberculosis",
      "author" : [ "Y. Zhang", "B. Heym", "B. Allen", "D. Young", "S. Cole" ],
      "venue" : "Nature 358 ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 1992
    }, {
      "title" : "Catalase In Vitro",
      "author" : [ "H. Aebi" ],
      "venue" : "Methods Enzymol,",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 1984
    }, {
      "title" : "Enzyme encapsulation in layer-bylayer engineered polymer multilayer capsules",
      "author" : [ "F. Caruso", "D. Trau", "H. Möhwald", "R. Renneberg" ],
      "venue" : "Langmuir 16 ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "S",
      "author" : [ "Y. Liu", "J. Du", "M. Yan", "M.Y. Lau", "J. Hu", "H. Han", "O.O. Yang" ],
      "venue" : "Liang,W.Wei, H. Wang, Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication, Nat. Nanotechnol. 8 ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells",
      "author" : [ "H. Chen", "J. Tian", "W. He", "Z. Guo" ],
      "venue" : "J. Am. Chem. Soc. 137 ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Enzyme encapsulation in nanoporous silica spheres",
      "author" : [ "Y. Wang", "F. Caruso" ],
      "venue" : "Chem. Commun. ",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Recyclable nanobiocatalyst for enantioselective sulfoxidation: facile fabrication and high performance of chloroperoxidase-coated magnetic nanoparticles with iron oxide core and polymer shell",
      "author" : [ "W. Wang", "Y. Xu", "D.I. Wang", "Z. Li" ],
      "venue" : "J. Am. Chem. Soc. 131 ",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Biomedical applications of electrostatic layer-by-layer nano-assembly of polymers",
      "author" : [ "H. Ai", "S.A. Jones", "Y.M. Lvov" ],
      "venue" : "enzymes, and nanoparticles, Cell Biochem. Biophys. 39 ",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Mesoporous silica spheres as supports for enzyme immobilization and encapsulation",
      "author" : [ "Y. Wang", "F. Caruso" ],
      "venue" : "Chem. Mater. 17 ",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "X",
      "author" : [ "Q. Chen" ],
      "venue" : "Wang, C.Wang, L. Feng, Y. Li, Z. Liu, Drug-induced self-assembly of modified albumins as nano-theranostics for tumor-targeted combination therapy, ACS Nano 9 ",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "An Imagable and photothermal “Abraxane-like” Nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors",
      "author" : [ "Q. Chen", "C. Liang", "C. Wang", "Z. Liu" ],
      "venue" : "Adv. Mater. 27 ",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "A self-assembled albumin-based Nanoprobe for in vivo Ratiometric photoacoustic pH imaging",
      "author" : [ "Q. Chen", "X. Liu", "J. Chen", "J. Zeng", "Z. Cheng", "Z. Liu" ],
      "venue" : "Adv. Mater. 27 ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Z",
      "author" : [ "Q. Chen" ],
      "venue" : "Liu, Albumin carriers for cancer theranostics: a conventional platform with new promise",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles",
      "author" : [ "M. Wang", "J.A. Zuris", "F. Meng", "H. Rees", "S. Sun", "P. Deng", "Y. Han", "X. Gao", "D. Pouli", "Q. Wu" ],
      "venue" : "Proc. Natl. Acad. Sci. 113 (2016) 2868–2873. lbumin/catalase as smart nano-theranostics for deep intra-tumoral oi.org/10.1016/j.jconrel.2016.11.006  11  Q. Chen et al. / Journal of Controlled Release xxx ",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dual-modal imaging-guided cancer synergistic phototherapy",
      "author" : [ "Z. Sheng", "D. Hu", "M. Zheng", "P. Zhao", "H. Liu", "D. Gao", "P. Gong", "G. Gao", "P. Zhang", "Y. Ma" ],
      "venue" : "ACS Nano 8 ",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imagingguided photothermal therapy",
      "author" : [ "Q. Chen", "C. Wang", "Z. Zhan", "W. He", "Z. Cheng", "Y. Li", "Z. Liu" ],
      "venue" : "Biomaterials 35 ",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "An albumin-based theranostic nanoagent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery",
      "author" : [ "Q. Chen", "C. Liang", "X. Wang", "J. He", "Y. Li", "Z. Liu" ],
      "venue" : "Biomaterials 35 ",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Albumin-NIR dye self-assembled nanoparticles for photoacoustic pH imaging and pH-responsive photothermal therapy effective for large tumors",
      "author" : [ "Q. Chen", "X. Liu", "J. Zeng", "Z. Cheng", "Z. Liu" ],
      "venue" : "Biomaterials 98 ",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Doxorubicinloaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types",
      "author" : [ "S. Bae", "K. Ma", "T.H. Kim", "E.S. Lee", "K.T. Oh", "E.-S. Park", "K.C. Lee", "Y.S. Youn" ],
      "venue" : "Biomaterials 33 ",
      "citeRegEx" : "48",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "A simple method for determination of serum catalase activity and revision of reference range",
      "author" : [ "L. Goth" ],
      "venue" : "Clin. Chim. Acta 196 ",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 1991
    }, {
      "title" : "PEG-functionalized iron oxide nanoclusters loaded with chlorin e6 for targeted",
      "author" : [ "Z. Li", "C. Wang", "L. Cheng", "H. Gong", "S. Yin", "Q. Gong", "Y. Li", "Z. Liu" ],
      "venue" : "NIR light induced, photodynamic therapy, Biomaterials 34 ",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Catalytic production of hydrogen peroxide and water by oxygen-tolerant [NiFe]-hydrogenase during H2 cycling in the presence of O2",
      "author" : [ "L. Lauterbach", "O. Lenz" ],
      "venue" : "J. Am. Chem. Soc. 135 (2013) 17897–17905. Please cite this article as: Q. Chen, et al., Drug-induced co-assembly of a penetration, hypoxia relieve, and s..., J. Control. Release ",
      "citeRegEx" : "51",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Assembly of catalase-based bioconjugates for enhanced anticancer efficiency of photodynamic therapy in vitro",
      "author" : [ "J. Zhao", "J. Fei", "C. Du", "W. Cui", "H. Ma", "J. Li" ],
      "venue" : "Chem. Commun. 49 ",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Harnessing photochemical internalization with dual degradable nanoparticles for combinatorial photo–chemotherapy",
      "author" : [ "G. Pasparakis", "T. Manouras", "M. Vamvakaki", "P. Argitis" ],
      "venue" : "Nat. Commun. 5 ",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy",
      "author" : [ "M. López-Lázaro" ],
      "venue" : "Cancer Lett. 252 ",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dualtracer immunohistochemistry",
      "author" : [ "X. Sun", "X.-F. Li", "J. Russell", "L. Xing", "M. Urano", "G.C. Li", "J.L. Humm", "C.C. Ling" ],
      "venue" : "Radiother. Oncol. 88 ",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level–dependent MR imaging",
      "author" : [ "L.J. Rich", "M. Seshadri" ],
      "venue" : "Radiology 275 ",
      "citeRegEx" : "56",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "In vivo photoacoustic lifetime imaging of tumor hypoxia in small animals",
      "author" : [ "Q. Shao", "E. Morgounova", "C. Jiang", "J. Choi", "J. Bischof", "S. Ashkenazi" ],
      "venue" : "J. Biomed. Opt. 18 ",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes in living mice",
      "author" : [ "K. Pu", "A.J. Shuhendler", "J.V. Jokerst", "J. Mei", "S.S. Gambhir", "Z. Bao", "J. Rao" ],
      "venue" : "Nat. Nanotechnol. 9 ",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Science to practice: can photoacoustic imaging be used to monitor tumor oxygenation and the effects of antivascular",
      "author" : [ "M.D. Pagel" ],
      "venue" : "chemotherapies? Radiology",
      "citeRegEx" : "59",
      "shortCiteRegEx" : "59",
      "year" : 2015
    } ],
    "referenceMentions" : [ {
      "referenceID" : 13,
      "context" : "and distribution of therapeutic nanoparticles within solid tumors [14].",
      "startOffset" : 66,
      "endOffset" : 70
    }, {
      "referenceID" : 14,
      "context" : "Another well-known feature of TME is insufficient oxygen supply, also known as hypoxia, within many types of solid tumors, particularly in the regions far from tumor blood vessels [15,16].",
      "startOffset" : 180,
      "endOffset" : 187
    }, {
      "referenceID" : 15,
      "context" : "Another well-known feature of TME is insufficient oxygen supply, also known as hypoxia, within many types of solid tumors, particularly in the regions far from tumor blood vessels [15,16].",
      "startOffset" : 180,
      "endOffset" : 187
    }, {
      "referenceID" : 22,
      "context" : "To date, various strategies including use of perfluorocarbon-based oxygen-carriers to transport oxygen into tumors [23,24] or in situ generation of oxygen from TME endogenous H2O2 (~50–100 μM), which is produced by the aberrant metabolism of cancer cells [11,25–29], have been explored to relieve the tumor hypoxia and improve therapeutic efficiency.",
      "startOffset" : 115,
      "endOffset" : 122
    }, {
      "referenceID" : 23,
      "context" : "To date, various strategies including use of perfluorocarbon-based oxygen-carriers to transport oxygen into tumors [23,24] or in situ generation of oxygen from TME endogenous H2O2 (~50–100 μM), which is produced by the aberrant metabolism of cancer cells [11,25–29], have been explored to relieve the tumor hypoxia and improve therapeutic efficiency.",
      "startOffset" : 115,
      "endOffset" : 122
    }, {
      "referenceID" : 31,
      "context" : "Thus, various strategies including encapsulation of this enzyme in inorganic nanoparticles or polymeric multilayer capsules have been developed to protect catalase from protease digestion to enable its tumor-targeted delivery [32,35].",
      "startOffset" : 226,
      "endOffset" : 233
    }, {
      "referenceID" : 34,
      "context" : "Thus, various strategies including encapsulation of this enzyme in inorganic nanoparticles or polymeric multilayer capsules have been developed to protect catalase from protease digestion to enable its tumor-targeted delivery [32,35].",
      "startOffset" : 226,
      "endOffset" : 233
    }, {
      "referenceID" : 47,
      "context" : "Furthermore, HSA-Ce6-CAT nanoparticles for control experiments were obtained by cross-linking HSA-Ce6 and CAT (w/w = 10:1) with glutaraldehyde [48].",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 48,
      "context" : "Catalase activity was determined by the Góth method [49].",
      "startOffset" : 52,
      "endOffset" : 56
    }, {
      "referenceID" : 49,
      "context" : "The method for the singlet oxygen detection was based on the protocol reported previously [50].",
      "startOffset" : 90,
      "endOffset" : 94
    }, {
      "referenceID" : 33,
      "context" : "Catalase, which has the ability to rapidly decompose H2O2 into H2O and O2, has been reported by many groups as an O2-envolving agent [34,51].",
      "startOffset" : 133,
      "endOffset" : 140
    }, {
      "referenceID" : 50,
      "context" : "Catalase, which has the ability to rapidly decompose H2O2 into H2O and O2, has been reported by many groups as an O2-envolving agent [34,51].",
      "startOffset" : 133,
      "endOffset" : 140
    }, {
      "referenceID" : 33,
      "context" : "Therefore, the PDT efficiency of HSACe6-Cat–PTX is expected to be significantly improved in the tumor microenvironment containing a certain amount of H2O2 [34,52].",
      "startOffset" : 155,
      "endOffset" : 162
    }, {
      "referenceID" : 51,
      "context" : "Therefore, the PDT efficiency of HSACe6-Cat–PTX is expected to be significantly improved in the tumor microenvironment containing a certain amount of H2O2 [34,52].",
      "startOffset" : 155,
      "endOffset" : 162
    }, {
      "referenceID" : 48,
      "context" : "The catalase activity of HSA-Ce6-Cat–PTX against proteases was determined by the Góth method [49].",
      "startOffset" : 93,
      "endOffset" : 97
    }, {
      "referenceID" : 52,
      "context" : "Interestingly, after laser irradiation, the diffused Ce6 fluorescence as well as the reduced Lysotracker fluorescence were observed, indicating that the photochemical internalization [53] trigger the release of the chemotherapeutic drugs into cytoplasm, resulting in the improved therapeutic efficiency.",
      "startOffset" : 183,
      "endOffset" : 187
    }, {
      "referenceID" : 24,
      "context" : "Considering catalase has the ability to decompose endogenous H2O2 within the tumor to produce oxygen [25,54,55], we then examined the therapeutic efficiency of HSA-Ce6–PTX and HSA-Ce6-Cat–PTX to 4T1 cells cultured under nitrogen atmosphere (5% CO2, 94% N2, 1% O2) for 24 h.",
      "startOffset" : 101,
      "endOffset" : 111
    }, {
      "referenceID" : 53,
      "context" : "Considering catalase has the ability to decompose endogenous H2O2 within the tumor to produce oxygen [25,54,55], we then examined the therapeutic efficiency of HSA-Ce6–PTX and HSA-Ce6-Cat–PTX to 4T1 cells cultured under nitrogen atmosphere (5% CO2, 94% N2, 1% O2) for 24 h.",
      "startOffset" : 101,
      "endOffset" : 111
    }, {
      "referenceID" : 54,
      "context" : "Considering catalase has the ability to decompose endogenous H2O2 within the tumor to produce oxygen [25,54,55], we then examined the therapeutic efficiency of HSA-Ce6–PTX and HSA-Ce6-Cat–PTX to 4T1 cells cultured under nitrogen atmosphere (5% CO2, 94% N2, 1% O2) for 24 h.",
      "startOffset" : 101,
      "endOffset" : 111
    }, {
      "referenceID" : 38,
      "context" : "Based on our previous studies [39,40], the stability of albumin nanoparticles induced by hydrophobic drug molecules (e.",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 39,
      "context" : "Based on our previous studies [39,40], the stability of albumin nanoparticles induced by hydrophobic drug molecules (e.",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 55,
      "context" : "spectra shift between oxygenated hemoglobin and deoxygenated hemoglobin [56,57].",
      "startOffset" : 72,
      "endOffset" : 79
    }, {
      "referenceID" : 56,
      "context" : "spectra shift between oxygenated hemoglobin and deoxygenated hemoglobin [56,57].",
      "startOffset" : 72,
      "endOffset" : 79
    }, {
      "referenceID" : 45,
      "context" : "On the other hand, it is known that Taxanes including PTX is able to induce apoptosis of neoplastic cells so as to decompress tumor blood vessels and lower interstitial fluid pressure in the tumor [46].",
      "startOffset" : 197,
      "endOffset" : 201
    }, {
      "referenceID" : 7,
      "context" : "Although intelligent albumin-MnO2 nanoparticles developed in our previous work are pH-/H2O2-responsive dissociable nano-carriers and have the ability tomodulate tumor hypoxia, the safety issues of inorganic component in the previous formulation and the significant amount of released Mn may be concerns to be addressed before its clinical translation [8].",
      "startOffset" : 351,
      "endOffset" : 354
    }, {
      "referenceID" : 38,
      "context" : "In future,wemay further incorporate tumor-targeting ligands into those albumin-based nanoparticles also by drug-induced self-assembly to realize active tumor targeting [39].",
      "startOffset" : 168,
      "endOffset" : 172
    } ],
    "year" : 2016,
    "abstractText" : "Article history: Received 29 July 2016 Received in revised form 25 October 2016 Accepted 9 November 2016 Available online xxxx The abnormal tumor microenvironment (TME) featured with hypoxia, acidosis, dense extracellular matrix and increased tumor interstitial fluid pressure is closely related with the resistance of tumors to various therapies. Herein, a unique type of biocompatible nanoscale delivery system is fabricated by utilizing a chemotherapeutic drug, paclitaxel (PTX), to induce co-assembly of catalase and human serum albumin (HSA), the latter of which is pre-modified with chlorine e6 (Ce6), forming smart multifunctional HSA-Ce6-Cat–PTX nanoparticles via a rather simple one-step method. Upon intravenous injection, HSA-Ce6-Cat–PTX nanoparticles show high tumor accumulation and efficient intra-tumoral diffusion, likely owning to their changeable sizes that can maintain large initial sizes (~100 nm) during blood circulation and transform into small protein-drug complexes (b20 nm) within the tumor. Meanwhile, catalase within those nanoparticles could trigger decomposition of endogenic TME H2O2 to generate oxygen in-situ so as to relieve tumor hypoxia. This effect together with PTXinduced intra-tumoral perfusion enhancement is able to dramatically modulate TME to favor the anti-tumor effect in the combined photodynamic/chemotherapy with HSA-Ce6-Cat–PTX. Thus, our work presents a simple drug-induced self-assembly strategy to fabricate enzyme-loaded therapeutic albumin nanoparticles for synergistic cancer combination therapy. © 2016 Published by Elsevier B.V.",
    "creator" : "Elsevier"
  }
}